Last reviewed · How we verify
intravenous Dexamethsone 4mg
Intravenous Dexamethasone 4mg, marketed by Poznan University of Medical Sciences, holds a position in the therapeutic landscape with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad clinical use, which supports its market presence. However, the primary risk is the upcoming patent expiry, which could lead to increased competition from generic versions.
At a glance
| Generic name | intravenous Dexamethsone 4mg |
|---|---|
| Sponsor | Poznan University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Dexamethasone Administration Route in PENG Block for Pediatric Hip Surgery (PHASE4)
- The Effect of Dexamethasone Administration Route on Pain and Inflammatory Response in PENG Block for Total Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous Dexamethsone 4mg CI brief — competitive landscape report
- intravenous Dexamethsone 4mg updates RSS · CI watch RSS
- Poznan University of Medical Sciences portfolio CI